- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04052659
Sintilimab (IBI308) in Combination With Chidamide and Azacitidine in Refractory or Relapsed PTCL
A Study to Evaluate the Efficacy and Safety of Sintilimab (IBI308) in Combination With Chidamide and Azacitidine in the Refractory or Relapsed PTCL: A Phase 2, Single-center, Single-arm, Open Label Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
To determine the objective response rate (ORR).
SECONDARY OBJECTIVES:
- To determine the complete response rate (CRR).
- To determine the duration of response (DOR).
- To determine the progression free survival (PFS).
- To determine the overall survival (OS).
- To determine the safety.
EXPLORATORY OBJECTIVES:
Assess the correlation between the expression of PD-L1, CD4, CD8, CD68 in tumor microenvironment and the efficacy of combined therapy in relapsed or refractory peripheral T-cell lymphoma.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Yuqin Song, Doctor
- Phone Number: 010-88196115
- Email: songyuqin622@163.com
Study Contact Backup
- Name: Zhitao Ying, Doctor
- Phone Number: 010-88196115
- Email: yingzhitao001@163.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100000
- BEIJING
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histopathologically confirmed PTCL;
- Disease status defined as relapsed or refractory after >=1 prior treatment lines;
- Prior use of HDACi or PD-1/PD-L1 antibodies or demethylation drugs is allowed;
- At least one measurable disease (defined as ≥ 1.5 cm in length-diameter, or 1.1~1.5 cm in length-diameter and >1.0 cm in short-diameter ) ;
- ECOG PS 0~2;
- Provide written informed consent for the trial;
- 18 ≤ age ≤ 80;
- Life expectancy ≥12 weeks;
- Adequate organ and bone marrow function, laboratory tests should be received within 7 days prior to the use of the research drug and meet the eligibility requirements;
- Subjects of reproductive potential must be willing to use adequate contraception during the course of the study and through 120 days after the last dose of study medication.
Exclusion Criteria:
- Known central nervous system lymphoma or cutaneous T-cell lymphoma;
- Received any immunesuppressive drugs within 4 weeks of the first dose of study medicationy, not including topical corticosteroids or systemic corticosteroids in physiological doses (≤10 mg/day prednisone or equivalent dose of other steroid);
- Patients with active autoimmune diseases requiring systematic treatment in the past two years;
- Received or plan to receive any attenuated vaccines within 4 weeks of the first dose of study medication;
- Received the last anti-tumor therapy within 4 weeks of the first dose of study medication or have not recovered (recovery defined as baseline or ≤ grade 1) from adverse events due to anti-cancer agents;
- Currently participating in an interventional clinical study, unless participating in observational study or during follow-up period of an interventional study;
- Received any investigational agent within 4 weeks of the first dose of study medication;
- Subjects with interstitial lung disease or lung disease that may interfere with the detection or treatment of suspected drug-related pulmonary toxicity;
- Other primary malignancy;
- Known history of allogeneic organ or allogeneic hemopoietic stem cell transplantation;
- Received autologous hemopoietic stem cell transplantation within 90 days of the first dose of study medication;
- Received major surgery or unhealed wound, ulcer or fracture within 4 weeks of the first dose of study medication;
- Active tuberculosis;
- Known primary immunodeficiency;
- Known allergy or hypersensitivity to any monoclonal antibodies or any components used in their preparation;
- Uncontrolled concomitant disease;
- Patients with active hepatitis. Patients who are positive for hepatitis B Surface Antigen (HBsAg) or hepatitis C Virus (HCV) antibodies at screening stage must pass further detection of hepatitis B Virus (HBV) DNA titer (no more than 50 IU/mL) and HCV RNA (no more than the lower limit of the detection method);
- History of gastrointestinal perforation and /or fistula within 6 months before enrollment;
- Hemophagocytic syndrome;
- Uncontrolled third space effusion, e.g. ascites or pleural effusion cannot be drained or controlled;
- Women who are pregnant or nursing;
- According to the researchers' judgment, patients' underlying condition may increase their risk of receiving research drug treatment, or confuse their judgment on toxic reactions;
- Other researchers consider it unsuitable for patients to participate in this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Treatment (sintilimab,chidamide and azacitidine)
Sintilimab: 200 mg IV, Q3W, d1 Chidamid: 30 mg PO, BIW, d1, d4 Azacidine: 100 mg SC, Q3W, d1-7 |
200 mg IV, every 3 weeks, d1
Other Names:
30 mg PO, 2 times every week, d1 and d4
Other Names:
100 mg SC, every 3 weeks, d1 to d7
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response rate (ORR) by Lugano 2014 up to 24 months
Time Frame: Up to 24 months
|
Proportion of subjects who achieve complete response (CR) or partial response (PR) by Lugano 2014 response criteria
|
Up to 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Complete remission rate (CRR) by Lugano 2014 up to 24 months
Time Frame: Up to 24 months
|
Proportion of subjects who achieve complete response (CR) by Lugano 2014 response criteria
|
Up to 24 months
|
Duration of response (DOR) up to 24 months
Time Frame: Up to 24 months
|
DOR is defined as the time from the date of first remission to the date of disease progression or death whichever is earlier
|
Up to 24 months
|
Progression free survival (PFS) up to 24 months
Time Frame: Up to 24 months
|
PFS is defined as the time from the treatment date to the date of disease progression per the Lugano 2014 Response Criteria or death regardless of cause
|
Up to 24 months
|
Overall survival (OS) up to 24 months
Time Frame: Up to 24 months
|
OS is defined as the time from treatment to the date of death
|
Up to 24 months
|
Incidence and Severity of adverse events by CTCAE v5.0 up to 90 days post-treatment
Time Frame: Up to 90 days post-treatment
|
Incidence and Severity of adverse events as assessed by CTCAE v5.0
|
Up to 90 days post-treatment
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Identification of potential biomarkers predictive of response to treatment
Time Frame: Up to 24 months
|
The correlation of clinical response with the expression of PD-L1, CD4, CD8, CD68 in tumor environment
|
Up to 24 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Yuqin Song, Doctor, Cancer Hospital of Beijing University
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Lymphoma
- Lymphoma, T-Cell
- Lymphoma, T-Cell, Peripheral
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Azacitidine
Other Study ID Numbers
- CIBI308Y016
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peripheral T-cell Lymphoma
-
The First Affiliated Hospital of Xiamen UniversityThe First Affiliated Hospital with Nanjing Medical University; Shanxi Province... and other collaboratorsRecruitingPeripheral T Cell Lymphoma | Relapsed Peripheral T-Cell Lymphoma | Refractory T-Cell LymphomaChina
-
National Cancer Centre, SingaporeMerck Sharp & Dohme LLC; National Medical Research Council (NMRC), SingaporeNot yet recruitingRefractory Peripheral T-Cell Lymphoma | Relapsed Peripheral T-Cell LymphomaSingapore
-
The Lymphoma Academic Research OrganisationCompletedRefractory Peripheral T-Cell Lymphoma | Relapsed Peripheral T-Cell LymphomaFrance, Belgium
-
Millennium Pharmaceuticals, Inc.CompletedRefractory Peripheral T-Cell Lymphoma | Relapsed Peripheral T-Cell LymphomaUnited States, France, Italy, Poland, United Kingdom, Belgium, Germany, Spain, Belarus, Israel, Portugal, Bulgaria, Turkey, Canada, New Zealand, Peru, Brazil, Russian Federation, Chile, Puerto Rico, Australia, Austria, Hungary, Nether... and more
-
University of Alabama at BirminghamTerminatedAnaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Peripheral T-cell Lymphomas | Adult T-cell Leukemia | Adult T-cell Lymphoma | Peripheral T-cell Lymphoma Unspecified | T/Null Cell Systemic Type | Cutaneous t-Cell Lymphoma With Nodal/Visceral DiseaseUnited States
-
Legend Biotech USA IncActive, not recruitingT-Cell Lymphoma | Peripheral T-Cell Lymphoma Refractory | Cutaneous T-Cell Lymphoma Refractory | Cutaneous T-Cell Lymphoma Recurrent | Peripheral T-Cell Lymphoma RecurrentUnited States
-
Karyopharm Therapeutics IncTerminatedCutaneous T-cell Lymphoma (CTCL) | Peripheral T-cell Lymphoma (PTCL)Australia, Singapore
-
BeiGeneCompletedCutaneous T-cell Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Adult Nasal Type Extranodal NK/T-cell Lymphoma | Anaplastic Large Cell Lymphoma, ALK-Positive | Extranodal NK/T-cell Lymphoma, Nasal Type | Peripheral T Cell Lymphoma | Extranodal NK/T-cell Lymphoma | Peripheral... and other conditionsChina, Taiwan, Germany, France, Canada, Italy
-
OnxeoTerminatedNon-Hodgkin's Lymphoma | Cutaneous T-Cell Lymphoma | Peripheral T-Cell LymphomaUnited States, Germany, Israel, France, Thailand
-
SciTech Development, LLCRush University Medical CenterRecruitingMycosis Fungoides | Cutaneous T-cell Lymphoma | Peripheral T-cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | T-cell Lymphoma | Cutaneous/Peripheral T-Cell Lymphoma | Peripheral T-Cell Lymphoma, Not Classified | Primary Cutaneous T-cell Lymphoma | Cutaneous T-Cell Lymphoma, Unspecified | Follicular... and other conditionsUnited States
Clinical Trials on Sintilimab
-
Beijing Tiantan HospitalRecruiting
-
RemeGen Co., Ltd.Recruiting
-
Innovent Biologics (Suzhou) Co. Ltd.CompletedAdvanced or Metastatic NSCLCChina
-
Innovent Biologics (Suzhou) Co. Ltd.Innovent Biologics (USA), Inc.WithdrawnMetastatic Cutaneous Melanoma | Unresectable Cutaneous MelanomaUnited States, Germany, France, Australia, Spain, Switzerland, United Kingdom
-
Shanghai YingLi Pharmaceutical Co. Ltd.RecruitingAdvanced Solid TumorsChina
-
Zhejiang Cancer HospitalRecruitingEsophageal Squamous Cell CarcinomaChina
-
Peking Union Medical College HospitalRecruiting
-
The First Hospital of Jilin UniversityActive, not recruitingLocally Advanced Rectal Cancer | PD-1 | Total Neoadjuvant Treatment | TislelizumabChina
-
Innovent Biologics (Suzhou) Co. Ltd.Completed
-
Wuhan UniversityRecruitingEsophageal Squamous Cell CarcinomaChina